$0.90
0.44% yesterday
Nasdaq, Nov 25, 10:01 pm CET
ISIN
US0044461004
Symbol
ACET
Sector
Industry

Adicet Bio Inc Stock price

$0.90
-0.50 35.43% 1M
-0.59 39.33% 6M
-0.99 52.17% YTD
-0.28 23.39% 1Y
-8.95 90.82% 3Y
-8.06 89.91% 5Y
-117.26 99.23% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.00 0.44%
ISIN
US0044461004
Symbol
ACET
Sector
Industry

Key metrics

Market capitalization $74.49m
Enterprise Value $-109.38m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 1.18
P/B ratio (TTM) P/B ratio 0.35
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-128.44m
Free Cash Flow (TTM) Free Cash Flow $-92.84m
Cash position $202.07m
EPS (TTM) EPS $-1.71
P/E forward negative
Short interest 4.93%
Show more

Is Adicet Bio Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Adicet Bio Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Adicet Bio Inc forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Adicet Bio Inc forecast:

Buy
75%
Hold
25%

Financial data from Adicet Bio Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 6.53 6.53
21% 21%
-
-6.53 -6.53
21% 21%
-
- Selling and Administrative Expenses 15 15
48% 48%
-
- Research and Development Expense 101 101
5% 5%
-
-122 -122
2% 2%
-
- Depreciation and Amortization 6.53 6.53
21% 21%
-
EBIT (Operating Income) EBIT -128 -128
3% 3%
-
Net Profit -118 -118
18% 18%
-

In millions USD.

Don't miss a Thing! We will send you all news about Adicet Bio Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adicet Bio Inc Stock News

Neutral
Business Wire
8 days ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the opening of enrollment for the Phase 1 clinical trial evaluating ADI-270 in patients with metastatic/advanced clear cell renal cell carcinoma (ccRCC). “Sol...
Neutral
Business Wire
8 days ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that the first LN patient has been dosed in the Phase 1 clinical trial evaluating ADI-001 in autoimmune diseases. “Dosing the first lupus nephritis patient in...
Neutral
Business Wire
10 days ago
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic, gamma delta T cell therapies for autoimmune diseases and cancer, today announced that clinical biomarker data from the ADI-001 Phase 1 GLEAN trial which demonstrates robust tissue homing, significant CAR T cell activation, and complete CD...
More Adicet Bio Inc News

Company Profile

resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA.

Head office United States
CEO Chen Schor
Employees 143
Founded 2014
Website www.adicetbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today